Milan 2012 Programme Registration Exhibition Hotels Exhibitor Listing Satellite Meetings Visa Information
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Finasterid-related floppy iris syndrome

Poster Details

First Author: A.Grzybowski POLAND

Co Author(s):    I. Winiarczyk              

Abstract Details


To discuss finasterid relations with floppy iris syndrome.


Intraoperative floppy iris syndrome has been described for the first time by Chang and Campbell in 2005. It is characterized by tree symptoms occurring during phacoemulsification 1) flaccid iris stroma, 2) propensity for the floppy iris stroma to prolapse toward the phaco and sideport incision despite proper wound construction, 3) progressive intraoperative pupil constriction. Preoperative often accompanied by a narrow pupil despite the using of mydriatics. IFIS is manifested in some 2-2,3% of patients.The symptoms of IFIS are closely linked to the admission of tamsulosin and other alpha-adrenergic blockers which are used to treat benign prostatic hyperplasia (BPH). Other adrenergic blockers are used in cardiology for the treatment of heart failure. Finasterid is a specific inhibitor of 5-alfa-reductase that inhibits conversion of testosterone to dihydrotestosterone. It is used to treat male pattern alopecia and benign prostatic hyperplasia.


Review of the literature and case report.


Previously described only a few cases of intraoperative floppy iris syndrome loose in patients taking finasteride. Wong et al described a 47-year-old patient treated with finasteride for 4 years due to androgenic alopecia, who manifested subcapsular cataract and during operation full-symptoms IFIS. Issa et al described the cases of two men treated with finasteride for benign prostatic hyperplasia. In both occurred twice IFIS during phacoemulsification procedures.


The use of finasterid can be associated with intraoperative floppy iris syndrome. Every patient who takes finasteride should be informed of the possibility of these complications. FINANCIAL DISCLOSURE?: No

Back to previous

loading Please wait while information is loading.